European myeloma experts recently developed guidelines for the appropriate management of side effects associated with novel agent therapy for older multiple myeloma patients. This article, Part 1 in a series, summarizes the guidelines for the management of Velcade-related side effects. Part 2 summarizes the European experts’ guidelines for the management of thalidomide-related side effects, Part 3 summarizes the guidelines for the management of Revlimid-related side effects, and Part 4 summarizes recommendations on novel agent use in specific patient…

Korean researchers recently found that the percentage of cancerous plasma cells in the bone marrow, measured on day 14 post transplant, may predict disease progression in multiple myeloma patients following high-dose chemotherapy and stem cell transplantation.

However, because their study was small and retrospective in nature, the Korean researchers suggested that further studies be conducted to confirm their findings.

The standard treatment for myeloma patients under the age of 65 years currently consists of high-dose chemotherapy, followed by autologous stem…

Results from a recent clinical study suggest that a new type of response, called an immunophenotypic response, strongly predicts disease progression in elderly multiple myeloma patients. Patients who achieved an immunophenotypic response had superior progression-free survival than patients who achieved a complete response or stringent complete response.

The authors suggested that testing for these three types of responses provides complementary information and that effort should be made to refine response criteria for multiple myeloma.

A number of previous studies have…

Results of a recent study indicate that obesity does not negatively affect outcomes after stem cell transplantation in multiple myeloma patients. In fact, obese patients treated with high-dose melphalan-based chemotherapy and total body irradiation before transplantation had a lower risk of relapse and better overall survival, compared to normal-weight patients.

The study authors concluded that obese multiple myeloma patients should not be excluded from stem cell transplantation due to their weight.

“Obese patients don’t seem to be at higher risk for severe…

Italian researchers recently found that most myeloma patients are able to collect sufficient stem cells after a short course of induction therapy with Revlimid, allowing them to undergo two consecutive stem cell transplants.

“Revlimid can be used safely before stem cell mobilization, provided that we use only four courses before mobilization and cyclophosphamide is used to mobilize,” said Dr. Antonio Palumbo, lead author of the study and a researcher at the University of Torino in Italy.

The current standard treatment…